TriangleL19IL2/L19TNF (NCT07228442)
L19IL2/L19TNF trial for Locally Advanced Cutaneous Squamous Cell Carcinoma (NCT07228442). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with locally advanced skin squamous-cell cancer that progressed on checkpoint immunotherapy or could not tolerate it. An injectable, measurable skin or subcutaneous lesion is required; visceral metastases are excluded.
The idea: L19IL2/L19TNF combines antibodies with immune-signaling proteins to concentrate immune stimulation around tumors. Weekly tumor injections last up to four weeks. A second course is optional for partial response or stable disease. Biopsies confirm response; researchers assess tumor control and safety.
This phase 2 study plans 92 patients. Philogen sponsors the study; five US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.